

Arkansas Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Arkansas from January 2017 through December 2017.

Key Arkansas Findings



Rejection Rate:

36%



Appeals Rate:

18%



Final Rejections:

1,000

Of health plans that received at least 50 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Arkansas State Employees **95%**
- BCBS AR **60%**
- Express Scripts **60%**
- Tricare Military Health SVC SYS **47%**

The following had **the lowest rates of rejection:**

- Humana Health Plan **13%**
- Aetna **10%**



The following table details claims data for the Arkansas managed care organizations that received at least 50 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
ARKANSAS STATE EMPLOYEES	95%	62	59
BCBS AR	60%	379	226
EXPRESS SCRIPTS	60%	52	31
TRICARE MILITARY HEALTH SVC SYS	47%	77	36
CIGNA HEALTHCARE	46%	74	34
UNITED HEALTH GROUP	38%	336	129
CVS HEALTH	33%	403	132
WELLCARE MANAGEMENT GROUP	20%	167	33
HUMANA HEALTH PLAN	13%	454	58
AETNA	10%	276	28

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

